Arvelle Therapeutics $180 million Series A financing

Overview:

• Swiss biotech company Arvelle Therapeutics has raised $180 million in series A financing.
• Avelle Therapeutics used the financing to acquire the exclusive rights to develop and commercialise cenobamate, a small molecule drug intended to treat focal seizures in adult patients, from SK Biopharmaceuticals.
• LSP, NovaQuest, BRV Capital Management, Andrea Partners and H.I.G. BioHealth Partners invested in the company.

Rajeeb Gurung - Researcher